Free Trial
NASDAQ:LMAT

LeMaitre Vascular (LMAT) Stock Price, News & Analysis

LeMaitre Vascular logo
$86.07 +2.58 (+3.09%)
Closing price 03/24/2025 04:00 PM Eastern
Extended Trading
$86.06 -0.01 (-0.01%)
As of 03/24/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About LeMaitre Vascular Stock (NASDAQ:LMAT)

Key Stats

Today's Range
$84.18
$86.34
50-Day Range
$78.82
$104.00
52-Week Range
$62.39
$109.58
Volume
146,580 shs
Average Volume
148,273 shs
Market Capitalization
$1.94 billion
P/E Ratio
47.03
Dividend Yield
0.93%
Price Target
$95.25
Consensus Rating
Moderate Buy

Company Overview

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Remove Ads

LeMaitre Vascular Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

LMAT MarketRank™: 

LeMaitre Vascular scored higher than 70% of companies evaluated by MarketBeat, and ranked 279th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LeMaitre Vascular has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LeMaitre Vascular has only been the subject of 4 research reports in the past 90 days.

  • Read more about LeMaitre Vascular's stock forecast and price target.
  • Earnings Growth

    Earnings for LeMaitre Vascular are expected to grow by 11.86% in the coming year, from $1.94 to $2.17 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LeMaitre Vascular is 47.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LeMaitre Vascular is 47.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.70.

  • Price to Earnings Growth Ratio

    LeMaitre Vascular has a PEG Ratio of 2.22. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    LeMaitre Vascular has a P/B Ratio of 6.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LeMaitre Vascular's valuation and earnings.
  • Percentage of Shares Shorted

    5.59% of the float of LeMaitre Vascular has been sold short.
  • Short Interest Ratio / Days to Cover

    LeMaitre Vascular has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in LeMaitre Vascular has recently decreased by 8.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    LeMaitre Vascular has a dividend yield of 0.94%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    LeMaitre Vascular has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of LeMaitre Vascular is 41.24%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 36.87% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.

  • Read more about LeMaitre Vascular's dividend.
  • Percentage of Shares Shorted

    5.59% of the float of LeMaitre Vascular has been sold short.
  • Short Interest Ratio / Days to Cover

    LeMaitre Vascular has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in LeMaitre Vascular has recently decreased by 8.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    LeMaitre Vascular has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for LeMaitre Vascular this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    Only 3 people have added LeMaitre Vascular to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,979.00 in company stock.

  • Percentage Held by Insiders

    10.79% of the stock of LeMaitre Vascular is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LeMaitre Vascular's insider trading history.
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LMAT Stock News Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
See More Headlines

LMAT Stock Analysis - Frequently Asked Questions

LeMaitre Vascular's stock was trading at $92.14 on January 1st, 2025. Since then, LMAT shares have decreased by 6.6% and is now trading at $86.07.
View the best growth stocks for 2025 here
.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings data on Thursday, February, 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. The medical instruments supplier had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. LeMaitre Vascular had a trailing twelve-month return on equity of 13.15% and a net margin of 19.40%.

The following companies are subsidiaries of LeMaitre Vascular: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and others.

LeMaitre Vascular's top institutional investors include Conestoga Capital Advisors LLC (7.53%), Vanguard Group Inc. (7.03%), Copeland Capital Management LLC (5.21%) and Geneva Capital Management LLC (3.85%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Lawrence J Jasinski, Bridget A Ross and John A Roush.
View institutional ownership trends
.

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
2/27/2025
Ex-Dividend for 3/27 Dividend
3/13/2025
Today
3/24/2025
Dividend Payable
3/27/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LMAT
Employees
490
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$95.25
High Stock Price Target
$110.00
Low Stock Price Target
$75.00
Potential Upside/Downside
+10.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
47.03
Forward P/E Ratio
44.37
P/E Growth
2.22
Net Income
$30.10 million
Pretax Margin
25.43%

Debt

Sales & Book Value

Annual Sales
$219.86 million
Cash Flow
$1.52 per share
Price / Cash Flow
56.52
Book Value
$13.38 per share
Price / Book
6.43

Miscellaneous

Free Float
20,058,000
Market Cap
$1.94 billion
Optionable
Optionable
Beta
0.89

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:LMAT) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners